Evidence map›Paper›PMID 37534517›Full record

Trial reportHaematologica2024

Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria.

Austin G Kulasekararaj, Anna-Elina Lehtinen, Cecily Forsyth, Shreyans Gandhi, Morag Griffin, Sixten Körper, Gabor Mikala, Petra Muus, Ulrik Overgaard, Christopher J Patriquin and 11 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03225287 (A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03225287 phase2terminatednot on this map

A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study

TypeinterventionalSponsorRa Pharmaceuticals, Inc.Ran2017 to 2021Enrolled19ConditionsParoxysmal Nocturnal Hemoglobinuria (PNH)ArmsZilucoplan (RA101495)
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 15 institutions in 8 countries.

Austin G KulasekararajKing's College Hospital-NHS Foundation Trust, NIHR/Wellcome King's Clinical Research Facility, London, UK and King's College London, London.
Anna-Elina LehtinenHelsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki.
Cecily ForsythGosford Hospital, Gosford, NSW.
Shreyans GandhiKing's College Hospital-NHS Foundation Trust, NIHR/Wellcome King's Clinical Research Facility, London, UK and King's College London, London.
Morag GriffinSt. James's University Hospital, Leeds.
Sixten KörperUniversity of Ulm, Institute of Transfusion Medicine, and Institute of Transfusion Medicine and Immunogenetics Ulm, Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm.
Gabor MikalaCentral Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Budapest.
Petra MuusKing's College Hospital-NHS Foundation Trust, NIHR/Wellcome King's Clinical Research Facility, London, UK and King's College London, London, UK; St. James's University Hospital, Leeds.
Ulrik OvergaardUniversity Hospital Copenhagen, Copenhagen, Denmark.
Christopher J PatriquinUniversity Health Network, Toronto, ON.
Humphrey PullonWaikato Hospital, Hamilton.
Yu-Min ShenUT Southwestern Medical Center, Dallas, TX.
Ruth SpearingChristchurch Hospital, Christchurch.
Jeff SzerPeter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC.
Guillemette De la BorderiePeter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC.
Petra W DudaUCB Pharma, Cambridge, MA.
Ramin Farzaneh-FarUCB Pharma, Cambridge, MA.
Sharan RagunathanUCB Pharma, Cambridge, MA.
Camil E SayeghUCB Pharma, Cambridge, MA.
Douangsone D VadysirisackUCB Pharma, Cambridge, MA.
Hubert SchrezenmeierUniversity of Ulm, Institute of Transfusion Medicine, and Institute of Transfusion Medicine and Immunogenetics Ulm, Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm. h.schrezenmeier@blutspende.de.
UCB Pharma (United States) · USPeter MacCallum Cancer Centre · AUChristchurch Hospital · NZCopenhagen University Hospital · DKGosford Hospital · AUHelsinki University Hospital · FIImmungenetics (Germany) · DEKing's College Hospital · GBKing's College Hospital NHS Foundation Trust · GBKing's College London · GBSouthwestern Medical CenterSt James's University Hospital · GBUniversität Ulm · DEUniversity Health Network · CAWaikato Hospital · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Complement C5Hemoglobinuria, ParoxysmalPeptides, CyclicHumansComplement C5Peptides, Cycliczilucoplan

Identifiers

PMID37534517
PMCPMC10905099
OpenAlexW4385514316

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.